對結腸直腸癌(大腸癌)的治療具有輔助性價值的一個醫療營養品
Jakab F, Shoenfeld Y, Balogh A, Nichelatti M, Hoffmann A, Kahan Z, Lapis K, Mayer A, Sapy P, Szentpetery F, Telekes A, Thurzo L, Vagvolgyi A, Hidvegi M. A medical nutriment has supportive value in the treatment of colorectal cancer, Br J Cancer 2003 Aug 4;89(3):465-9
中文摘要
這份研究中，一百七十名結腸直腸癌(大腸癌)的患者於接受標準治療性手術後，其中六十六名患者持續飲用AVEMAR作為互補治療，其餘沒有使用AVEMAR的患者則作為對照。經六個月的試驗期，統計並分析比較二者的腫瘤惡化相關事件發生。結果顯示使用AVEMAR的受試者，整體的腫瘤惡化率皆顯著低於僅接受標準治療而未使用 AVEMAR的對照組。
英文摘要
MSC (Avemar) is a medical nutriment of which preclinical and observational clinical studies suggested an antimetastatic activity with no toxicity. This open-label cohort trial has compared anticancer treatments plus MSC (9 g once daily) vs anticancer treatments alone in colorectal patients, enrolled from three oncosurgical centres; cohort allocation was on the basis of patients' choice. Sixty-six colorectal cancer patients received MSC supplement for more than 6 months and 104 patients served as controls (anticancer therapies alone): no statistical difference was noted in the time from diagnosis to the last visit between the two groups. End-point analysis revealed that progression-related events were significantly less frequent in the MSC group (new recurrences: 3.0 vs 17.3%, P<0.01; new metastases: 7.6 vs 23.1%, P<0.01; deaths: 12.1 vs 31.7%, P<0.01). Survival analysis showed significant improvements in the MSC group regarding progression-free (P=0.0184) and overall survivals (P=0.0278) probabilities. Survival predictors in Cox's proportional hazards were UICC stage and MSC treatment. Continuous supplementation of anticancer therapies with MSC for more than 6 months is beneficial to patients with colorectal cancer in terms of overall and progression-free survival.
